Brian M. Slomovitz, MD, discusses the phase 3 DUO-E and AtTEnd trials investigating the use immunotherapy in endometrial cancer, as presented at the 2023 ESMO Congress.
Brian M. Slomovitz, MD, discusses the optimal role for PARP inhibition in patients with ovarian cancer, highlighting its efficacy in those harboring BRCA mutations.